Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 4/2010

01-04-2010 | Review Article

Multiple Sclerosis in the Elderly Patient

Authors: Amer Awad, Dr Olaf Stüve

Published in: Drugs & Aging | Issue 4/2010

Login to get access

Abstract

Multiple sclerosis (MS) is an acquired inflammatory demyelinating disease of the CNS that is typically diagnosed in the second or third decade of life. It is generally believed that over the last few decades the life expectancy of patients with adult onset MS (AOMS) has approached that of the general population as a result of better medical and nursing care. Thus, an increasing number of MS patients are entering or have reached senescence. A second group of elderly patients with MS that may be very different in terms of disease pathogenesis are patients with late onset MS (LOMS). The diagnosis in LOMS patients can be challenging because of a large number of age-associated MS differential diagnoses, atypical presentations, a low index of suspicion and the lack of diagnostic criteria specific to this age group. Also, specific problems these patients encounter have only recently become a focus of attention. Changes in renal and hepatic function with age, in addition to the coexistence of medical co-morbidities, require special attention in the management of elderly patients with MS. In this review we outline the characteristics of senescent AOMS and LOMS patients. In addition, we discuss therapeutic strategies in elderly patients with MS based on our knowledge of immunosenescence and age-associated characteristics of this disorder. Given the overall aging of the population, focusing on these two patient groups appears highly relevant.
Literature
1.
Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153–87PubMedCrossRef
2.
Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85(3): 299–302PubMedCrossRef
3.
Stüve O, Zamvil SS. Neurologic diseases. In: Parslow TG, Stites DP, Terr AI, et al., editors. Medical immunology. San Francisco (CA): McGraw Hill, 2001: 510–26
4.
Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992; 31(3): 333–6PubMedCrossRef
5.
Poser CM. The epidemiology of multiple sclerosis: a general overview. Ann Neurol 1994 Dec; 36Suppl. 2: S180–93PubMedCrossRef
6.
Hanefeld F, Bauer HJ, Christen HJ, et al. Multiple sclerosis in childhood: report of 15 cases. Brain Dev 1991; 13(6): 410–6PubMedCrossRef
7.
Duquette P, Murray TJ, Pleines J, et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr 1987; 111(3): 359–63PubMedCrossRef
8.
Poser S, Raun NE, Poser W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta Neurol Scand 1982; 66(3): 355–62PubMedCrossRef
9.
Kurtzke JF, Page WF, Murphy FM, et al. Epidemiology of multiple sclerosis in US veterans: 4, age at onset. Neuroepidemiology 1992; 11(4-6): 226–35PubMedCrossRef
10.
Liguori M, Marrosu MG, Pugliatti M, et al. Age at onset in multiple sclerosis. Neurol Sci 2000; 21: S825–9PubMedCrossRef
11.
Manzi S. Epidemiology of systemic lupus erythematosus. Am J Manag Care 2001; 7: S474–9PubMed
12.
Alarcon GS. Epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21: 589–604PubMed
13.
Fox RI. Epidemiology, pathogenesis, animal models, and treatment of Sjogren’s syndrome. Curr Opin Rheumatol 1994; 6: 501–8PubMedCrossRef
14.
Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study: predictive value of the early clinical course. Brain 1989; 112: 1419–28PubMedCrossRef
15.
Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29: 53–62PubMedCrossRef
16.
Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000; 47: 831–5PubMedCrossRef
17.
Vukusic S, Confavreux C. Primary and secondary progressive multiple sclerosis. J Neurol Sci 2003; 206: 153–5PubMedCrossRef
18.
Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain 1997; 120: 1085–96PubMedCrossRef
19.
Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281–300PubMedCrossRef
20.
Riise T, Grønning M, Fernández O, et al. Early prognostic factors for disability in multiple sclerosis: a European multicenter study. Acta Neurol Scand 1992; 85: 212–8PubMedCrossRef
21.
Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995; 58: 300–6PubMedCrossRef
22.
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907–11PubMedCrossRef
23.
Minden SL, Frankel D, Hadden LS, et al. Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. NeuroRehabilitation 2004; 19: 55–67PubMed
24.
Baum HM, Rothschild BB. The incidence and prevalence of multiple sclerosis. Ann Neurol 1981; 10: 420–8PubMedCrossRef
25.
Kranz JMS, Kurland LT, Schuman LM, et al. Multiple sclerosis in Olmsted and Mower Counties, Minnesota. Neuroepidemiology 1983; 2: 206–18CrossRef
26.
Kurtzke JF, Beebe GW, Norman Jr EJ. Epidemiology of multiple sclerosis in US veterans: I, race, sex, and geographic distribution. Neurology 1979; 29: 1228–35PubMedCrossRef
27.
Minden SL, Marder WD. Multiple sclerosis: a statistical portrait: a compendium of data on demographics, disability and health services utilization in the United States: report to the National Multiple Sclerosis Society. Cambridge (MA): Abt Associates Inc., 1993
28.
Nelson LM, Hamman RF, Thompson DS, et al. Higher than expected prevalence of multiple sclerosis in northern Colorado: dependence on methodologic issues. Neuroepidemiology 1986; 5: 17–28PubMedCrossRef
29.
Wynn DR, Rodriguez M, O’Fallon WM, et al. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990; 40: 780–6PubMedCrossRef
30.
Finlayson M. Health and social profile of older adults with MS: findings from three studies. Int J MS Care 2002; 4: 139–51
31.
Klewer J, Pohlau D, Nippert I, et al. Problems reported by elderly patients with multiple sclerosis. J Neurosci Nurs 2001; 33: 167–71PubMedCrossRef
32.
Polliack ML, Barak Y, Achiron A. Late onset multiple sclerosis. J Am Geriatr Soc 2001; 49: 168–71PubMedCrossRef
33.
Bauer HJ, Hanefled F. Multiple sclerosis: its impact from childhood to old age. London: W.B. Saunders, 1993
34.
Phadke JG. Clinical aspects of multiple sclerosis in northeast Scotland with particular reference to its course and prognosis. Brain 1990; 113: 1597–628PubMedCrossRef
35.
White AD, Swingler RJ, Compston DA. Features of multiple sclerosis in older patients in South Wales. Gerontology 1990; 36:159–64PubMedCrossRef
36.
Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year follow up study. Neurology 2004; 62: 51–9PubMedCrossRef
37.
Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430–8PubMedCrossRef
38.
Kantarci O, Siva A, Eraksoy M, et al., Turkish Multiple Sclerosis Study Group (TUMSSG). Survival and predictors of disability in Turkish MS patients. Neurology 1998; 51: 765–72PubMedCrossRef
39.
Bergamaschi R, Berzuini C, Romani A, et al. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 2001; 189: 13–21PubMedCrossRef
40.
Amato MP, Ponziani G, Bartolozzi ML, et al. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168: 96–106PubMedCrossRef
41.
Patty D, Boilo A, Vorobeichik G. Multiple sclerosis with early and late disease onset. In: McDonald WI, Nose-worthy J, editors. Multiple sclerosis 2. Boston (MA): Butterworth Heinemann, 2003: 285–302CrossRef
42.
Noseworthy J, Paty D, Wonnacott T, et al. Multiple sclerosis after age of 50. Neurology 1983; 33: 1537–44PubMedCrossRef
43.
Cazzullo CL, Ghezzi A, Marforio S, et al. Clinical picture of multiple sclerosis with late onset. Acta Neurol Scand 1978; 58: 190–6PubMedCrossRef
44.
45.
Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66: 172–7PubMedCrossRef
46.
Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002 Dec 24; 59(12): 1922–8PubMedCrossRef
47.
Tremlett H, Devonshire V. Is late onset multiple sclerosis associated with a worse outcome? Neurology 2006; 67: 954–9PubMedCrossRef
48.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–52PubMedCrossRef
49.
Wolfson C, Wolfson DB. The latent period of multiple sclerosis: a critical review. Epidemiology 1993; 4: 464–70PubMedCrossRef
50.
Lu T, Pan Y, Kao SY, et al. Gene regulation and DNA damage in the ageing human brain. Nature 2004; 429: 883–91PubMedCrossRef
51.
Sim FJ, Zhao C, Penderis J, et al. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002; 22: 2451–9PubMed
52.
Kis B, Rumberg B, Berlit P. Clinical characteristics of patients with late-onset multiple sclerosis. J Neurol 2008; 255: 697–702PubMedCrossRef
53.
Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radio-logically isolated syndrome. Neurology 2009; 72: 800–5PubMedCrossRef
54.
55.
Gomez-Garcia AO, Fernandez-Concepcion O, Milan-Ginjauma E. Clinical-epidemiological characteristics of late onset multiple sclerosis. Rev Neurol 1997; 25: 1863–6PubMed
56.
Moreira MA, Felipe E, Mendes MF, et al. Multiple sclerosis: descriptive study of its clinical forms in 302 cases. Arq Neuropsiquiatr 2000; 58: 460–6PubMedCrossRef
57.
Hawkins SA, McDonnel GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999; 67: 148–52PubMedCrossRef
58.
Herndon RM. Multiple sclerosis mimics. Adv Neurol 2006; 98: 161–6PubMed
59.
Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993; 52: 506–16PubMed
60.
Sawcer S, Jones HB, Feakes R, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996; 13: 464–8PubMedCrossRef
61.
Kuokkanen S, Sundvall M, Terwilliger JD, et al. A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2. Nat Genet 1996; 13:477–80PubMedCrossRef
62.
Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nat Genet 1996; 13: 472–6PubMedCrossRef
63.
Haines JL, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex: the Multiple Sclerosis Genetics Group. Nat Genet 1996; 13: 469–71PubMedCrossRef
64.
Barcellos LF, Oksenberg JR, Begovich AB, et al., Multiple Sclerosis Genetics Group. HLA-DR2 Dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003; 72: 710–6PubMedCrossRef
65.
Villoslada P, Barcellos LF, Rio J, et al. The HLA locus and multiple sclerosis in Spain: role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol 2002; 130: 194–201PubMedCrossRef
66.
Mazurek AA, Shi J. APOE epsilon4 allele is associated with cognitive impairment in patients with multiple sclerosis [letter]. Neurology 2008; 71: 1203PubMedCrossRef
67.
Shi J, Zhao CB, Vollmer TL, et al. APOE epsilon 4 allele is associated with cognitive impairment in patients with multiple sclerosis. Neurology 2008; 70: 185–90PubMedCrossRef
68.
Pinholt M, Frederiksen JL, Andersen PS, et al. Apo E in multiple sclerosis and optic neuritis: the apo E-epsilon4 allele is associated with progression of multiple sclerosis. Mult Scler 2005; 11: 511–5PubMedCrossRef
69.
Enzinger C, Ropele S, Smith S, et al. Accelerated evolution of brain atrophy and “black holes” in MS patients with APOE-epsilon 4. Ann Neurol 2004; 55: 563–9PubMedCrossRef
70.
Becker KG. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001; 57: 2148–9PubMedCrossRef
71.
Fazekas F, Strasser-Fuchs S, Kollegger H, et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57: 853–7PubMedCrossRef
72.
Orlando L. AD gene accelerates MS. Trends Neurosci 2001; 24: 257
73.
Chapman J, Vinokurov S, Achiron A, et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001; 56: 312–6PubMedCrossRef
74.
Portaccio E, Goretti B, Zipoli V, et al. APOE-{varepsilon}4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. Mult Scler 2009; 15(12): 1489–94PubMedCrossRef
75.
van der Walt A, Stankovich J, Bahlo M, et al. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology 2009; 73: 1018–25PubMedCrossRef
76.
Guerrero AL, Laherrán E, Gutiérrez F, et al. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score. Acta Neurol Scand 2008; 117: 21–5PubMed
77.
Ramagopalan SV, Deluca GC, Morrison KM, et al. No effect of APOE and PVRL2 on the clinical outcome of multiple sclerosis. J Neuroimmunol 2007 May; 186:156–60PubMedCrossRef
78.
Koutsis G, Panas M, Karadima G, et al. APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score. J Neurol 2007; 254: 394–5PubMedCrossRef
79.
Sedano MI, Calmarza P, Perez L, et al. No association of apolipoprotein E epsilon4 genotype with faster progression or less recovery of relapses in a Spanish cohort of multiple sclerosis. Mult Scler 2006; 12: 13–8PubMedCrossRef
80.
Zwemmer JN, van Veen T, van Winsen L, et al. No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. Mult Scler 2004; 10: 272–7PubMedCrossRef
81.
Weatherby SJ, Mann CL, Fryer AA, et al. No association between the APOE epsilon4 allele and outcome and susceptibility in primary progressive multiple sclerosis [letter]. J Neurol Neurosurg Psychiatry 2000; 68: 532CrossRef
82.
Savettieri G, Andreoli V, Bonavita S, et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol 2003; 250: 1094–8PubMedCrossRef
83.
Stüve O, Korth C, Gabatto P, et al. Genetic polymorphism at codon 129 of the prion protein gene is not associated with multiple sclerosis. Arch Neurol 2009; 66: 280–1PubMedCrossRef
84.
Vandenbroeck K, Martino G, Marrosu M, et al. Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. J Neuroimmunol 1997; 76: 189–92PubMedCrossRef
85.
86.
Fransson C, Mooney J, Kinane DF, et al. Differences in the inflammatory response in young and old human subjects during the course of experimental gingivitis. J Clin Periodontol 1999; 26: 453–60PubMedCrossRef
87.
Niwa Y, Kasama T, Miyachi Y, et al. Neutrophil chemotaxis, phagocytosis and parameters of reactive oxygen species in human aging: cross-sectional and longitudinal studies. Life Sci 1989; 44: 1655–64PubMedCrossRef
88.
Fulop T, Foris G, Leovey A. Age-related changes in cAMP and cGMP levels during phagocytosis in human polymorphonuclear leukocytes. Mech Ageing Dev 1984; 27:233–7PubMedCrossRef
89.
Biasi D, Carletto A, Dell’Agnola C, et al. Neutrophil migration, oxidative metabolism, and adhesion in elderly and young subjects. Inflammation 1996; 20: 673–81PubMedCrossRef
90.
Damtew B, Spagnuolo PJ, Goldsmith GG, et al. Neutrophil adhesion in the elderly: inhibitory effects of plasma from elderly patients. Clin Immunol Immunopathol 1990; 54: 247–55PubMedCrossRef
91.
Tortorella C, Piazzolla G, Spaccavento F, et al. Age-related effects of oxidative metabolism and cyclic AMP signaling on neutrophil apoptosis. Mech Ageing Dev 1999; 110: 195–205PubMedCrossRef
92.
Tortorella C, Piazzolla G, Spaccavento F, et al. Spontaneous and Fas-induced apoptotic cell death in aged neutrophils. J Clin Immunol 1998; 18: 321–9PubMedCrossRef
93.
Fülöp Jr T, Fouquet C, Allaire P, et al. Changes in apoptosis of human polymorphonuclear granulocytes with aging. Mech Ageing Dev 1997; 96: 15–34PubMedCrossRef
94.
Steger MM, Maczek C, Grubeck-Loebenstein B. Morphologically and functionally intact dendritic cells can be derived from the peripheral blood of aged individuals. Clin Exp Immunol 1996; 105: 544–50PubMedCrossRef
95.
Lung TL, Saurwein-Teissl M, Parson W, et al. Unimpaired dendritic cells can be derived from monocytes in old age and can mobilize residual function in senescent T cells. Vaccine 2000; 18: 1606–12PubMedCrossRef
96.
Pietschmann P, Hahn P, Kudlacek S, et al. Surface markers and transendothelial migration of dendritic cells from elderly subjects. Exp Gerontol 2000; 35: 213–24PubMedCrossRef
97.
Komatsubara S, Cinader B, Muramatsu S. Polymorphism of age-related changes in stimulatory capacity of murine dendritic cells. Mech Ageing Dev 1986; 37: 163–73PubMedCrossRef
98.
Renshaw M, Rockwell J, Engleman C, et al. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 2002; 169: 4697–701PubMed
99.
Karpus WJ, Kennedy KJ. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997; 62: 681–7PubMed
100.
McManus C, Berman JW, Brett FM, et al. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998; 86: 20–9PubMedCrossRef
101.
Swift ME, Burns AL, Gray KL, et al. Age-related alterations in the inflammatory response to dermal injury. J Invest Dermatol 2001; 117: 1027–35PubMedCrossRef
102.
Makinodan T. Studies on the influence of age on immune response to understand the biology of immunosenescence. Exp Gerontol 1998; 33: 27–38PubMedCrossRef
103.
104.
105.
106.
Haynes BF, Markert ML, Sempowski GD, et al. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000; 18: 529–60PubMedCrossRef
107.
Steinmann GG, Klaus B, Muller-Hermelink HK. The involution of the ageing human thymic epithelium is independent of puberty: a morphometric study. Scand J Immunol 1985; 22: 563–75PubMedCrossRef
108.
109.
Aronson M. Hypothesis: involution of the thymus with aging–programmed and beneficial. Thymus 1991; 18: 7–13PubMed
110.
Smith SM, Ossa-Gomez LJ. A quantitative histologic comparison of the thymus in 100 healthy and diseased adults. Am J Clin Pathol 1981; 76: 657–65PubMed
111.
Bertho JM, Demarquay C, Moulian N, et al. Phenotypic and immunohistological analyses of the human adult thymus: evidence for an active thymus during adult life. Cell Immunol 1997; 179: 30–40PubMedCrossRef
112.
Scollay R, Wilson A, Shortman K. Thymus cell migration: analysis of thymus emigrants with markers that distinguish medullary thymocytes from peripheral T cells. J Immunol 1984; 132: 1089–94PubMed
113.
Penit C, Vasseur F. Expansion of mature thymocyte subsets before emigration to the periphery. J Immunol 1997; 159:4848–56PubMed
114.
Mackall CL, Bare CV, Granger LA, et al. Thymic-in-dependent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996; 156:4609–16PubMed
115.
Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89: 3700–7PubMed
116.
Mackall CL, Hakim FT, Gress RE. T-cell regeneration: all repertoires are not created equal. Immunol Today 1997; 18: 245–51PubMedCrossRef
117.
Mackall CL, Granger L, Sheard MA, et al. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 1993; 82: 2585–94PubMed
118.
Alter-Wolf S, Blomberg BB, Riley RL. Old mice retain bone marrow B1 progenitors, but lose B2 precursors, and exhibit altered immature B cell phenotype and light chain usage. Mech Ageing Dev 2009; 130: 401–8PubMedCrossRef
119.
Prineas JW, McDonald WI. Demyelinating diseases. In: Graham DI, Lantos PL, editors. Greenfield’s neuropathology. New York: Oxford University Press, 1997: 813–96
120.
Raine CS. Demyelinating diseases. In: Davis RL, Robertson DM, editors. Textbook of neuropathology. New York: Williams and Wilkins, 1997: 627–14
121.
Lassmann H, Raine CS, Antel J, et al. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 1998; 86: 213–7PubMedCrossRef
122.
Lucchinetti C, Bruck W, Parisi J, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 1999; 122: 2279–95PubMedCrossRef
123.
Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175–89PubMedCrossRef
124.
Thompson AJ, Kermode AG, MacManus DG, et al. Pathogenesis of progressive multiple sclerosis. Lancet 1989; 1: 1322–3PubMedCrossRef
125.
de Seze J, Delalande S, Michelin E, et al. Brain MRI in late-onset multiple sclerosis. Eur J Neurol 2005; 12: 241–4PubMedCrossRef
126.
Tartaglino LM, Friedman DP, Flanders AE, et al. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 1995; 195: 725–32PubMed
127.
Delalande S, de Seze J, Ferriby D, et al. Late onset MS. Rev Neurol 2002; 158: 1082–7PubMed
128.
Stenager EN, Stenager E, Koch-Henriksen N, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 1992; 55: 542–5PubMedCrossRef
129.
Turner AP, Williams RM, Bowen JD, et al. Suicidal ideation in multiple sclerosis. Arch Phys Med Rehabil 2006; 87: 1073–8PubMedCrossRef
130.
Fleming ST, Blake Jr RL. Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol 1994; 47: 1127–32PubMedCrossRef
131.
Allen NB, Lichtman JH, Cohen HW, et al. Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology 2008; 30: 234–8PubMedCrossRef
132.
Fleming ST. Multiple sclerosis as comorbidity: a study of resource utilization and outcomes of care. Clin Perform Qual Health Care 1995; 3: 23–30PubMed
133.
Dal Bianco A, Bradl M, Frischer J, et al. Multiple sclerosis and Alzheimer’s disease. Ann Neurol 2008; 63: 174–83CrossRef
134.
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I, clinical results of a multi-center, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61CrossRef
135.
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial. Neurology 1995; 45: 1268–76PubMedCrossRef
136.
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285–94PubMedCrossRef
137.
European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multi-center randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–7CrossRef
138.
The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a response in relapsing-remitting MS: the OWIMS Study. Neurology 1999; 53: 679–86CrossRef
139.
Comi G, Filippi M, Wolinsky JS, the European and Canadian Glatiramer Acetate Study Group. European/Canadian multi-center double blind, randomized placebo controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290–7PubMedCrossRef
140.
Polman C, Barkhof F, Kappos L, et al., European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003; 9: 342–8PubMedCrossRef
141.
Miller DH, Khan OA, Sheremata WA, et al., International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing MS. N Engl J Med 2003; 348: 15–23PubMedCrossRef
142.
Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788–95PubMedCrossRef
143.
Hemmer B, Frohman E, Hartung HP, et al. Central nervous system infections: a potential complication of systemic immunotherapy. Curr Opin Neurol 2006; 19: 271–6PubMedCrossRef
144.
Le Couteur DG, McLean AJ. The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34: 359–73PubMedCrossRef
145.
Mühlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999; 45: 243–53PubMedCrossRef
146.
Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol Ther 2000; 38: 243–53
147.
Baldwin Jr JG. Hematopoietic function in the elderly. Ann Intern Med 1988; 148: 2544–6CrossRef
Metadata
Title
Multiple Sclerosis in the Elderly Patient
Authors
Amer Awad
Dr Olaf Stüve
Publication date
01-04-2010
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2010
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11532120-000000000-00000

Other articles of this Issue 4/2010

Drugs & Aging 4/2010 Go to the issue

Review Article

Use of Hydromorphone, with Particular Reference to the OROS® Formulation, in the Elderly

Therapy In Practice

General Anaesthesia in Elderly Patients with Cardiovascular Disorders

Original Research Article

Validity of the Finnish Prescription Register for Measuring Psychotropic Drug Exposures among Elderly Finns

Review Article

Assessment and Management of Pressure Ulcers in the Elderly

Review Article

Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinson’s Disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits